NewEdge Wealth LLC Has $3.19 Million Stock Holdings in HCA Healthcare, Inc. $HCA

NewEdge Wealth LLC cut its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 24.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,747 shares of the company’s stock after selling 2,196 shares during the period. NewEdge Wealth LLC’s holdings in HCA Healthcare were worth $3,193,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sumitomo Life Insurance Co. lifted its holdings in shares of HCA Healthcare by 1.0% in the fourth quarter. Sumitomo Life Insurance Co. now owns 2,026 shares of the company’s stock worth $946,000 after acquiring an additional 20 shares during the last quarter. MJP Associates Inc. ADV lifted its stake in shares of HCA Healthcare by 2.9% in the 4th quarter. MJP Associates Inc. ADV now owns 749 shares of the company’s stock valued at $350,000 after acquiring an additional 21 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its position in HCA Healthcare by 7.5% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 300 shares of the company’s stock valued at $140,000 after purchasing an additional 21 shares during the last quarter. Anchyra Partners LLC grew its holdings in shares of HCA Healthcare by 3.7% during the first quarter. Anchyra Partners LLC now owns 587 shares of the company’s stock worth $278,000 after purchasing an additional 21 shares during the last quarter. Finally, Plato Investment Management Ltd boosted its position in HCA Healthcare by 0.6% during the 4th quarter. Plato Investment Management Ltd now owns 3,908 shares of the company’s stock worth $1,833,000 after buying an additional 22 shares during the period. Institutional investors own 62.73% of the company’s stock.

Analysts Set New Price Targets

HCA has been the topic of several analyst reports. Cantor Fitzgerald reduced their price objective on shares of HCA Healthcare from $588.00 to $525.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 7th. Robert W. Baird reduced their price target on HCA Healthcare from $450.00 to $442.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Barclays lowered their price objective on HCA Healthcare from $427.00 to $402.00 and set an “equal weight” rating for the company in a research report on Thursday, July 16th. JPMorgan Chase & Co. decreased their target price on shares of HCA Healthcare from $535.00 to $490.00 and set a “neutral” rating for the company in a research report on Tuesday, May 19th. Finally, Stephens dropped their price target on shares of HCA Healthcare from $560.00 to $530.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Fourteen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, HCA Healthcare has an average rating of “Moderate Buy” and a consensus price target of $483.45.

More HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA beat Q2 earnings estimates, reporting $7.59 per share versus expectations around $7.56-$7.57, while revenue rose 8.7% year over year to $20.23 billion and also topped estimates. HCA Healthcare earnings report
• Positive Sentiment: Management cited strong admissions and higher revenue per admission as key drivers of the quarter, suggesting healthy demand trends across its hospital network. Zacks article on HCA Q2 results
• Neutral Sentiment: HCA said its updated guidance is consistent with its earlier preview, so the quarter appears to confirm previously signaled results rather than deliver a major surprise. BusinessWire Q2 results
• Negative Sentiment: The company trimmed parts of its 2026 outlook, pointing to higher expenses and weaker surgical volumes as headwinds that could limit margin expansion. Zacks guidance revision article
• Negative Sentiment: Separate investor-law-firm investigations into HCA may add some legal overhang, though these notices are not operational results. Pomerantz investor alert

HCA Healthcare Trading Up 1.5%

Shares of NYSE HCA opened at $382.28 on Friday. The firm has a market capitalization of $84.80 billion, a P/E ratio of 13.15, a P/E/G ratio of 1.27 and a beta of 1.12. The firm’s 50-day moving average price is $386.95 and its 200-day moving average price is $453.73. HCA Healthcare, Inc. has a 1-year low of $330.00 and a 1-year high of $556.52.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, July 24th. The company reported $7.59 EPS for the quarter, beating analysts’ consensus estimates of $7.56 by $0.03. HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.The business had revenue of $20.23 billion during the quarter, compared to analyst estimates of $19.76 billion. During the same period in the previous year, the company posted $6.84 EPS. The firm’s revenue was up 8.7% compared to the same quarter last year. Equities research analysts forecast that HCA Healthcare, Inc. will post 29.19 EPS for the current year.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.